Characteristics That Affect the Long-term Clinical Outcome and Stroke Recurrence in Ischaemic Stroke Patients With Basilar Artery Atherosclerosis

Characteristics That Affect the Long-term Clinical Outcome and Stroke Recurrence in Ischaemic Stroke Patients With Basilar Artery Atherosclerosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Characteristics That Affect the Long-term Clinical Outcome and Stroke Recurrence in Ischaemic Stroke Patients With Basilar Artery Atherosclerosis yasemin dinç, rifat ozpar, Gizem MESUT, farid hojjati, serhat gokce, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3867836/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract İntroduction : Posterior circulation stroke differs from anterior circulation stroke in etiopathogenesis. Studies have shown that the most common stroke aetiology in posterior circulation stroke is ischemic stroke due to large vessel atherosclerosis. However, even under aggressive medical treatment, the risk of recurrent ischemic stroke in ischemic stroke due to intracranial atherosclerotic stenosis remains high. This study aims to obtain the rate of atherosclerotic disease of the BA in our ischemic stroke population, to determine its symptomatology, and to determine the factors affecting clinical outcome and ischaemic stroke recurrence in the symptomatic group. Material method : we included 107 patients who were diagnosed with acute ischemic stroke with basilar artery stenosis. Results According to the results of our study, the degree of stenosis in atherosclerotic stenosis of the symptomatic BA was found to be an independent risk factor for stroke recurrence. Independent risk factors for unfavourable clinical outcomes in these patients were determined as female gender, stenosis being in the proximal segment, stroke mechanism being from artery to artery embolism, and congestive heart failure. Discussion The most striking result of our study is that clinical outcome was found to be closely related to the female gender, the stroke mechanism being artery-to-artery embolism, and the stenosis is in the proximal segment. If stroke mechanisms were evaluated more clearly, it would likely help provide individualized treatments. Health sciences/Neurology/Neurological disorders/Stroke Health sciences/Risk factors Health sciences/Neurology/Neurological disorders/Cerebrovascular disorders/Stroke intracranial atherosclerotic disease basilar artery infarction basilar artery stenting acute ischaemic stroke Figures Figure 1 Figure 2 Figure 3 Figure 4 INTRODUCTION Posterior circulation stroke affects the vertebrobasilar artery system and constitutes 20–25% of all ischaemic stroke (IS) cases [ 1 ]. It differs from anterior circulation stroke in etiopathogenesis. Studies have shown that the most common stroke aetiology in posterior circulation stroke is IS due to large artery atherosclerosis [ 2 , 3 ]. The basilar artery (BA) is the major artery of the posterior circulation and provides the main blood supply to this vascular region [ 4 ]. The incidence of BA occlusion isn’t known exactly, but it is estimated to account for 1% of all stroke cases [ 5 ]. Although atherosclerotic disease of the BA is rare, it is characterised by high mortality and stroke recurrence [ 6 ]. Atherosclerotic disease of the BA can have varied presentations and is asymptomatic in some patients. The clinical spectrum in symptomatic patients includes heterogeneous features that can range from minor deficits to coma and death [ 7 , 8 ]. New endovascular treatment options, which are increasingly available, have expanded the treatment options for these patients. On the basis of the data from the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial, BA stenting is recommended for patients with recurrent IS with symptomatic BA atherosclerotic stenosis who are undergoing aggressive medical treatment [ 9 , 10 ]. However, even under aggressive medical treatment, the risk of recurrent IS due to intracranial atherosclerotic stenosis remains high. IS is a heterogeneous group of diseases precipitated by many complicated mechanisms [ 11 ]. This study aimed to determine the incidence rate and symptoms of atherosclerotic disease of the BA in an IS population and the factors that affect the clinical outcomes and IS recurrence in symptomatic patients. MATERIALS AND METHODS In this study, 107 IS patients with atherosclerotic stenosis in the BA who were followed up in our tertiary center between 1 January 2019 and 1 January 2022, were included in the study. The Clinical Research Ethics Committee of the Bursa Uludag University, Faculty of Medicine approved the study (26 September 2023;2023-18/24). Need for informed consent was waived by The Clinical Research Ethics Committee of the Bursa Uludag University, Faculty of Medicine. This study was carried out in accordance with the guidelines in the Declaration of Helsinki. The inclusion criteria for the study were patients diagnosed with IS with clear aetiology and atherosclerotic stenosis in the BA in the emergency who were regularly examined at the neurology outpatient clinic. The exclusion criteria were failure to clarify the stroke aetiology, BA occlusion, and non-atherosclerotic stenosis (dissection, moyamoya disease) in the BA, being vertebral artery or posterior cerebral artery has more than 50 percent atherosclerotic stenosis. Between 1 January 2018 and 1 January 2022, 3214 patients were followed up, and 107 patients were included in the study according to the inclusion and exclusion criteria. All patients diagnosed with IS in the emergency department were admitted to the neurology service for further examination and treatment. All patients underwent brain and neck computed tomographic (CT) angiography, cranial magnetic resonance imaging (MRI), transthoracic echocardiography, and 24-hour rhythm Holter monitoring. In the epicrisis, their medical histories were recorded, including previous diseases, smoking habits, coronary artery disease (CAD), congestive heart failure, hypertension (HT), and diabetes mellitus (DM). The patients' hemogram, biochemistry results, low-density-lipoprotein (mg/dL), (LDL) levels, and HbA1c (%) values were evaluated during their hospitalisation in the neurology ward. During clinical follow-up, the aim was to keep the LDL level 7% were evaluated on the basis of endocrinology findings, and HbA1c and LDL values were checked every 3 months. The patients' brain and neck CT angiograms were evaluated by a radiologist (B.H.) with 23 years of neuroradiology experience who was blinded to the clinical findings. The degree of stenosis was determined using the NASCET method. The posterior cerebral collateral score was determined by evaluating the posterior communicating arteries (PCOMs). All patients were evaluated for the presence and diameter of both PCOMs, according to the following scores: dominant PCOM, 2 points; hypoplastic PCOM, 1 point; and no PCOMs, 0 points. The total scores ranged from 0 to 4. Scores from 0 to 1 were considered bad collateral scores, and scores from 2 to 4 were good collateral scores. The patients' stroke aetiologies were determined using the TOAST (trial of ORG 10172 in acute stroke treatment) classification [ 12 ]. A BA stenosis causing an IS was considered symptomatic. Whether the BA was symptomatic or not was decided by a stroke neurologist. The BA was evaluated in 3 segments: proximal, middle, and distal (Fig. 1 ). The stroke mechanisms were evaluated by dividing them into 4 types: artery-to-artery embolism, perforatory stroke, haemodynamic stroke, and IS due to BA occlusion (Fig. 2 ) [ 13 ]. In the 3rd month, the patients' clinical outcomes were determined using the modified Rankin scale (0–2, favourable outcomes and 3–6, unfavourable clinical outcomes). All the patients underwent regular checkups at the neurology outpatient clinic, where any stroke recurrence was recorded. The patients were followed in accordance with the American Heart Association guidelines. BA stenting was performed in patients with recurrent IS who were undergoing aggressive medical treatment. Statistical analysis The patients with atherosclerotic stenosis of the BA were categorised as either symptomatic or non-symptomatic. Receiver-operating characteristic (ROC) analysis was performed to determine the cut-off value of the degree of stenosis. The patients with symptomatic BA stenosis were then categorised according to whether they had stroke recurrence or not and their clinical outcomes. The clinical properties of the patients in both groups were analysed and compared. A statistical analysis was implemented using the IBM SPSS Statistics 25.0 package (IBM Corp., Armonk, NY). The Shapiro-Wilk test was used to determine the normality of the data distribution. Mean ± SD values were determined for the normally distributed variables, and median (Q1–Q3) values were determined for the non-normally distributed variables. An independent sample T test was performed to analyze the normally distributed variables between the two independent groups, and the Whitney U test was performed for the non-normally distributed variables. Frequencies and percentages were determined for the categorical variables. The Pearson chi-square test or Fisher exact test was performed to analyse the categorical variables for comparison between the groups. The binary logistic regression model included the variables found to be significant in the univariate analyses. Differences with p values > 0.05 were recognised as statistically significant. RESULTS A total of 3285 patients with acute IS were followed up between January 2018 and January 2022 at the Department of Neurology of the Uludag University Faculty of Medicine. A total of 107 patients with atherosclerotic stenosis in the BA who met the inclusion criteria were included in the study. Of these patients, 39 were female, and 68 were male. The mean age was 67.98 ± 9.33 years for all the patients, 67.08 ± 9.51 years for the male patients, and 69.53 ± 8.90 years for the female patients, indicating statistically similar mean ages between the male and female patients (p > 0.05). When the patients' risk factors were evaluated, 88 patients had HT, 64 had diabetes mellitus (DM), 59 were smokers, 31 had congestive heart failure, 45 had CAD, and 15 had atrial fibrillation (AF). According to stroke aetiology, 77 patients had an IS due to large artery atherosclerosis, 15 had an IS due to cardioembolism, 8 had an IS due to small vessel disease, 1 had an IS due to other causes, and 6 had an IS due to undetermined causes. When the location of the BA stenosis was examined, atherosclerotic stenosis was detected in the proximal basilar segment in 56 patients, in the mid-basilar segment in 59, and in the distal basilar segment in 7. The BA atherosclerotic stenosis was multisegmented in 13 patients and symptomatic in 69 patients. BA stenting was performed in 29 patients. As shown in Table 1, the BA atherosclerotic stenosis was symptomatic in 32 of the 56 patients with atherosclerotic stenosis in the proximal segment of the BA. A ROC analysis was performed to evaluate the level of stenosis in the patients with atherosclerotic stenosis in the proximal BA and to differentiate the symptomatic and non-symptomatic patients. The area under the ROC was 0.784 (p 70%, and the sensitivity and specificity corresponding to this cut-off value were 54.55% and 95.83%, respectively (Figure 3). Of the patients with symptomatic proximal BA atherosclerosis, 24 had an unfavourable clinical outcome, and 8 had a favourable clinical outcome. IS recurrence was observed in 15 patients with symptomatic proximal artery stenosis. When the stroke mechanisms were evaluated, artery-to-artery embolism occurred in 19 patients; penetrating artery infarction, in 18; haemodynamic stroke, in 6; and BA occlusion, in 4. The stroke in 13 patients occurred with a mixed mechanism. The BA atherosclerotic stenosis was symptomatic in 42 of the 59 patients with atherosclerotic stenosis in the mid-basilar segment. A ROC analysis was performed to evaluate the level of stenosis in the patients with atherosclerotic stenosis in the mid-basilar segment and to differentiate between the symptomatic and non-symptomatic patients. The area under the ROC was 0.718 (p 70%, and the sensitivity and specificity corresponding to this cut-off value were 52.38% and 88.24%, respectively (Figure 4). Of the patients with symptomatic mid-basilar atherosclerosis, 30 had a favourable clinical outcome, and 12 had an unfavourable clinical outcome. IS recurrence was observed in 15 patients with symptomatic mid-basilary stenosis. When the stroke mechanisms were evaluated, artery-to-artery embolism occurred in 15 patients; IS due to penetrating artery infarction, in 31; IS with a mixed mechanism, in 7; and BA occlusion, in 5. IS occurred with a mixed mechanism in 15 patients. When the demographic, clinical, and radiological properties of the IS patients with symptomatic BA stenosis and stroke recurrence were examined, the significant variables were artery-to-artery embolism (p = 0.027), BA occlusion (p < 0.001), or a mixed mechanism as the stroke mechanism (p < 0.001); haemoglobin level (p = 0.030); and degree of stenosis (p < 0.001; Table 2). However, no significant statistical relationship was found between stroke recurrence in the patients with symptomatic BA stenosis and age; sex; the presence of DM, HT, smoking, AF, congestive heart failure, or CAD; clinical outcomes; haemodynamic infarction or perforatory stroke as the stroke mechanism; and stenotic segments of the BA (p > 0.05; Table 2). Among the variables with a statistically significant relationship with symptomatic BA atherosclerotic stenosis and stroke recurrence that were evaluated using binary logistic regression, the most significant was the degree of stenosis (p < 0.001; odds ratio [OR], 1.074; Table 3). When the demographic, clinical, and radiological properties of the IS patients with symptomatic BA stenosis and clinical outcomes were examined, the significant variables were sex (p = 0.033), congestive heart failure (p = 0.050); artery-to-artery embolism (p = 0.008), BA occlusion (p < 0.001), or mixed mechanism as the stroke mechanism (p = 0.050); stenosis in the proximal basilary segments (p = 0.007); and stenosis in the mid-basilary segments (p = 0.020; Table 4). However, no significant statistical relationships were found between the clinical outcomes of the patients with symptomatic BA stenosis and age; the presence of HT, DM, smoking, AF, or congestive heart failure; perforatory stroke, haemodynamic stroke, or BA occlusion as the stroke mechanism; stenosis in the distal basilar segment; multi-segment stenosis; stroke recurrence; degree of stenosis; and BA stenting procedure (p > 0.05; Table 4). Among the variables with a statistically significant relationship with symptomatic BA atherosclerotic stenosis and unfavourable clinical outcomes that were evaluated using binary logistic regression, the most significant were sex (p = 0.06; OR, 9.776), congestive heart failure (p = 0.013; OR, 10.133), artery-to-artery embolism as the stroke mechanism (p = 0.042; OR, 3.874), atherosclerotic stenosis in the proximal BA (p = 0.022; OR, 4.716; Table 5). DISCUSSION According to the results of this study, the degree of atherosclerotic stenosis in symptomatic BA was an independent risk factor of stroke recurrence. The independent risk factors of unfavourable clinical outcomes in these patients were female sex, stenosis in the proximal segment, artery-to-artery embolism as the stroke mechanism, and congestive heart failure. The incidence of intracranial atherosclerotic disease is increasing with the ageing of society. A recent study reported that intracranial atherosclerotic stenosis most frequently occurs in the BA in IS patients [ 14 ]. In patients with IS due to intracranial atherosclerotic disease, stenting is recommended in the presence of recurrent IS under aggressive medical treatment. This recommendation is based on data from the SAMMPRIS trial [ 9 , 10 ]. However, even under aggressive medical treatment, the risk of recurrent IS due to intracranial atherosclerotic stenosis remains high. In our study, atherosclerotic stenosis of the BA was detected in 107 patients, of whom 69 (64.48%) were symptomatic. The mean follow-up period of the asymptomatic patients was 28.00 ± 18.034 months. None of the patients in the asymptomatic group had IS under aggressive medical treatment. The mean follow-up period in the symptomatic group was 25.53 ± 17.842 months. Of the 69 symptomatic patients, 30 (43.47%) had recurrent IS during the follow-up period. As this incidence rate was based on real-life data, it is much higher than those reported in randomised studies [ 10 ]. In our study, stenosis was detected in the proximal BA in 32 patients, in the mid-basilar segment in 42, and in the distal BA in 6. The stenosis was multisegmented in 13 patients. According to the findings of this study, atherosclerotic stenosis was most frequent in the mid-basilar segment but was rare in the distal BA. Similar incidence rates were obtained from the data reported by Edgar et al. [ 6 ]. The degree of stenosis was established to be an independent risk factor of stroke recurrence in patients with symptomatic BA stenosis. According to the data from the Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis (WASID) trial, the degree of stenosis is related to stroke recurrence [ 15 ]. In our study, the independent risk factor of unfavourable clinical outcomes was female sex. The relationships between sex and IS and atherosclerosis are complex. Atherosclerosis has a different course in women and men. Atherosclerotic lesions progress slowly starting from the fourth and fifth decades in men and progress rapidly in women, starting from the sixth decade [ 16 – 18 ]. Studies have indicated that stroke has a worse clinical outcome in women [ 19 ]. To our knowledge, no studies have reported the relationship between sex and IS due to BA atherosclerosis. Data from randomised studies that evaluated symptomatic intracranial atherosclerotic stenosis have indicated that while no sex-related difference was found in the Chinese Intracranial Atherosclerosis (CICAS) trial, female sex was found to be a poor prognostic factor in the WASID trial [ 15 , 20 ]. The most common stroke mechanism in patients with symptomatic BA atherosclerosis is perforatory stroke. MRI studies have shown that BA plaques have a long distribution and affect the ventral, dorsal, and lateral walls equally. These plaques do not have the same characteristics as those in the coronary and middle cerebral arteries. In addition, plaques in the BA tend to settle adjacent to the orifices of the penetrating arteries [ 21 ]. This can explain why the most common stroke mechanism is perforatory stroke. Arterial-to-artery stroke mechanism is an independent risk factor of unfavourable clinical outcomes. A recent study found a correlation between the morphological features of plaques and IS mechanism due to symptomatic posterior intracranial atherosclerosis. The authors found that unstable plaques with a higher plaque burden and irregular surfaces were symptomatic of artery-to-artery embolism [ 22 ]. In intracranial atherosclerotic disease, IS due to an artery-to-artery embolic stroke mechanism is a poor prognostic factor [ 6 , 13 ]. Unfavourable clinical outcome is another independent risk factor. Congestive heart failure is quite common in the stroke population. It is also an important risk factor of IS in the normal population [ 23 – 26 ]. Morbidity and mortality rates were found to be higher in IS patients with congestive heart failure [ 27 ]. This relationship may be the result of the close relationship between heart failure and atherosclerotic vascular disease. Limitations of the study The major limitation of this study is due to its retrospective nature and data from a single centre. More accurate information can be obtained through multi-centre prospective studies. Conclusion The most remarkable result of our study is that clinical outcomes were closely related to the female sex, artery-to-artery embolism as the stroke mechanism, and stenosis in the proximal segment. In patients with symptomatic BA stenosis, studies are needed to examine the effects of IS mechanisms and plaque morphologies on long-term stroke recurrence and clinical outcomes. Stroke mechanisms must be evaluated more clearly so that individualised treatments can be provided to these patients. Declarations Author Contribution Author Contribution:Concepts: YDDesign: YDDefinition Of İntellectual Content:MB, YDLiterature Search:YD, GM, FH, EOA, FSClinical Studies: YD, GM, FH, EOA, FSExperimental Studies:-Data Acquisition:YD, GM, FH, EOA, FSData Analysis: DS, YD, RO, GM, FH, SGStatistical Analysis: DS, YDManuscript Preparation:YD, EOA, FSManuscript Editing: MB, BHManuscript Review: MB, BHGuarantor: YDCorresponding Author: YD Data availability: All authors accept to share data if it is necessary References Merwick A., Werring D. Posterior circulation ischaemic stroke. Bmj. 2014; 348:3175. Pirson F., et al. Etiology of large vessel occlusion posterior circulation stroke: results of the MR CLEAN Registry. Stroke 2022;53:2468–2477. Caplan LR.,et al. New England medical center posterior circulation registry. Ann Neurol 2004;56:389–98. Caplan LR. Primer on cerebrovascular diseases. London, United Kingdom: Academic Press is an imprint of Elsevier; 2017. Israeli-Korn SD., et al. Ischemic stroke due to acute basilar artery occlusion: proportion and outcomes. Isr Med Assoc J 2010; 12: 671–75. Samaniego EA., et al. Stroke mechanisms and outcomes of isolated symptomatic basilar artery stenosis.Stroke Vasc Neurol. 2019; 4:189–197. Mattle HP., Arnold M., Lindsberg PJ., Schonewille WJ., Schroth G. Basilar artery occlusion. Lancet Neurol 2011; 10: 100214. Voetsch B., DeWitt LD., Pessin MS., Caplan LR. Basilar Artery Occlusive Disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2004;61(4):496–504. doi: 10.1001/archneur.61.4.496 Kleindorfer, D.O., et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021, 52, 364–467 Derdeyn, C. P et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. The Lancet, 2014;383(9914), 333–341. Dinç Y., Bakar M., Hakyemez B. Causes of ischemic stroke in patients with atrial fibrillation. Turk J Neurol 2020; 26: 311–315. Adams Jr., et al. "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment." stroke 24.1 (1993): 35–41. Feng X., Chan KL., Lan L., Abrigo J., Liu J., Fang H., Xu Y., Soo Y., Leng X., Leung TW. Stroke mechanisms in symptomatic intracranial atherosclerotic disease: classification and clinical implications. Stroke. 2019;50:2692–2699. Dinç Y., et all.Evaluation of intracranial atherosclerotic disease risk factors in patients with acute ischeamic stroke. Neurology Asia 2023,28(4):809–816. Chimowitz MI., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–1316. Bae HJ., et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis 2007;24:355–60. López-Cancio E., et al. The Barcelona-Asymptomatic Intracranial Atherosclerosis (AsIA) study: prevalence and risk factors. Atherosclerosis. 2012;221:221–225. Pu Y., et al. Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke 2013;44:2109–14. Reeves MJ., et all. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915–926. Pu Y., et all. Chinese IntraCranial AtheroSclerosis (CICAS) Study Group: Sex differences do not exist in outcomes among stroke patients with intracranial atherosclerosis in China: subgroup analysis from the Chinese intracranial atherosclerosis study. Neuroepidemiology 2017;48:48–54. Yu J., et al. Plaque distribution of low-grade basilar artery atherosclerosis and its clinical relevance. BMC Neurol 2017;17(1), 1–6. Song X,. et al. Association of Plaque Morphology With Stroke Mechanism in Patients With Symptomatic Posterior Circulation ICAD. Neurology, 2022,99: 2708–2717. Kim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke. 2018;20(1):33–45. Gottdiener JS., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631–9. Jelinek MV., Ansari MZ. Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. Aust N Z J Med. 1998;28:799–804. 22. Witt, BJ. et al. Ischemic stroke after heart failure: a community-based study. Am Heart J. 2006;152:102–9. Siedler, G. et all. Heart failure in ischemic stroke: relevance for acute care and outcome. Stroke, 2019;50(11): 3051–3056. Tables Table 1: Clinical properties of proxymal and mid-basilar artery stenosis Properties Symptomatic proximal basilar artery stenosis n=56 Symptomatic mid-basilar stenosis n=59 Symptomatic basilar artery stenosis 32(57.14%) 42(71.18%) Stroke recurrence due to basilary artery stenosis 15(26.78%) 15(25.42%) Stroke mechanism artery-to-artery embolism due to basilary artery stenosis 19(33.92%) 15(25.42%) Perforators stroke due to basilary artery stenosis 18(32.14%) 31(52.54%) Hemodynamic stoke due to basilary artery stenosis 6(10.71%) 7(11.86%) Stroke due to basilar artery occlusion 4(7.14%) 5(8.47%) Mix mechanism 13(23.21%) 15(25.42%) Favorable clinical outcome 8(14.28%) 30(50.84%) Unfavorable clinical outcome 24(42.85%) 12(20.33%) Follow-up perıod of patıents (Month) 23.50 ±17.63 29.93 ±17.78 Table 2. Evaluation of variables affecting stroke recurrence in acute ischemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery Variables Ischemic Stroke Due to Symptomatic Basilar Artery Atherosclerotic stenosis with Stroke Recurrence (n=30) Ischemic Stroke Due to Symptomatic Basilar Artery Atherosclerotic stenosis without Stroke Recurrence (n=39) p-value Age* 66.50±7.97 67.64±10.15 0.614 Sex** (male gender) 19(63.33%) 19(48.71%) 0.226 Diabetes** 19(63.33%) 26(66.66%) 0.773 Hypertension** 26(86.66%) 31(79.48%) 0.435 Smoker** 16(53.33%) 20(51.28%) 0.886 Atrial fibrilation** 16(53.33%) 20(51.28%) 0.646 Congestive heart failure** 4(13.33%) 10(25.64%) 0.208 Coroner artery disease** 10(33.33%) 15(38.46%) 0.660 Hemoglobin(g/dL)* 13.25(11.85,14.00) 13.80(12.58,14.70) 0.030 LDL(mg/dL)* 151.50(100.00,185.00) 138.50(112.25,174.75) 0.607 Stroke mechanism Artery-to-artery embolism ** 18(60%) 10(25.64%) 0.027 Perforators infarction** 16(48.48%) 28(71.79%) 0.114 Hemodynamic infarction 7(23.23%) 5(12.82%) 0.253 Basilar artery occlusion 9(30%) 0(0%) <0.001 Mix mechanism 18(60%) 8(20.51%) <0.001 Stenotic segment of the basilar artery Proximal segment** 15(50%) 17(43.58%) 0.506 Middle segment** 15(50%) 27(69.23%) 0.105 Distal segment** 3(10%) 3(7.69%) 1.000 Multisegment stenosis** 3(10%) 6(15.28%) 0.722 Stenosis degree(%) 66,28±20.70 85.50±10.77 <0.001 Clinical outcome** Unfavorable clinical outcome 11(%36.66) 11(%28.20) 0.455 Posterior collateral scores (poor collateral scores) 13(43.33) 14(35.89) 0.530 Significant variables are shown in bold. *Mann-Witney U test, **Pearson chi-square test/continuity correction test/Fisher Exact test.Abbreviations: LDL, Low-Density Lipoprotein. Table 3. Significant variables of stroke recurrence in acute ischaemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery p-value Odds ratio lower upper %95 C.I Stroke mechanism being artery to artery embolism Ref: Absent vs present 0.151 2.315 0.736 7.283 Stenosis degree <0.001 1.074 1.029 1.119 Heamoglobin(g/dL) 0.393 0.986 0.899 1.043 Significance of the model p<.001. Significant variables are shown in bold. Ref = references, vs = versus. Table 4: Table 2. Evaluation of variables affecting clinical outcomes in acute ischemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery Variables Patients with acute stroke due to basilar artery stenosis with unfavorable clinical outcome n=22 Patients with acute stroke due to basilar artery stenosis with favorable clinical outcome n=47 p-value Age 70.00±7.91 65.80±9.55 0.078 Sex (male gender) 8(%36.36) 30(%52.63) 0.033 Hypertension 18(%81.81) 39(%68.42) 1.000 Diyabetes mellitus 16(%72.72) 29(%61.70) 0.370 Smoker 9(%40.90) 27(%57.44) 0.200 Atrial fibrilation 1(%4.54) 4(%8.51) 1.000 Congestive heart failure 8(%36.36) 6(%17.76) 0.050 Coroner artery disease 9(%40.90) 16(%34.04) 0.580 Stroke mechanism Artery-to-artery embolism 15(%68.18) 16(%34.04) 0.008 Perforators stroke 11(%50.00) 33(%70.21) 0.104 Hemodynamic stroke 4(%18.18) 8(%17.02) 1.000 Basilar artery occlusion 5(%22.72) 4(%8.51) 0.132 Mix mechanism 12(%54.54) 14(%29.78) 0.050 Segment of basilary artery Proximal segment 15(%68.18) 17(%36.17) 0.007 Mid-basilar segment 9(%40.90) 33(%70.21) 0.020 Distal segment 3(%13.63) 3(%6.38) 0.375 Multi-segment stenosis 4(%18.18) 5(%10.63) 0.452 Stroke recurrence 11(%50.00) 19(%40.42) 0.455 Degree of stenosis 74.00(57.50,95,00) 80.00(60.00,90.00) 0.891 Basilar artery stenting 6(%27.27) 21(%44.68) 0.167 Posterior collateral scores (poor collateral scores) 8(%36.66) 19(%40.42) 0.747 Significant variables are shown in bold. *Mann-Witney U test, **Pearson chi-square test/continuity correction test/Fisher Exact test. Table 5. Significant variables of clinical outcome in acute ischaemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery p-value Odds ratio lower Upper %95 C.I Sex Ref: female gender 0.006 9.776 1.049 14.285 Congestive heart failure Ref: present vs absent 0.013 10.133 1.625 63.181 Stroke mechanism being artery-to-artery embolism Ref: present vs absent 0.042 3.874 1.049 14.285 Atherosclerotic stenosis in the proximal basilar artery Ref: present vs absent 0.022 4.716 1.245 17.868 Significance of the model < 0.001. Significant variables are shown in bold. Ref = references, vs = versus. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3867836","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":270956104,"identity":"4c7795a7-9ebc-44e5-b5a0-cb4a19b450f5","order_by":0,"name":"yasemin dinç","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYNACAwbGBgbm4z8+NoB4jI0HiNTCliA5s4FBAqilgQgtIGUMPAbSvGAtDAx4tRgcP/7w0Y2CO7L90m0JxrY7bOp02w8Dbamxicap5UyOsXGOwTPjmXMOH0jOPZMmYXYmEajlWFpuAy4tB3LYpHMMDiduuJGWcDi37bCE2QGgFsaGw7i1nH/+/DdIy/4bOYbNliAt5x8S0HIjwYwZbItEjjEzI0jLDQK2SN54YwxymPGMG2lpjL1taZLbbgBtScDjF77z6Q8/5/w5LNs/I/kYw882G34zoMiDDzU2OLUoHMAqnIBDOQjI4zJrFIyCUTAKRgEcAABYuGsFIB8pwAAAAABJRU5ErkJggg==","orcid":"","institution":"Uludağ University","correspondingAuthor":true,"prefix":"","firstName":"yasemin","middleName":"","lastName":"dinç","suffix":""},{"id":270956105,"identity":"80a95956-2539-4804-ae1a-ef8bbdbafc2f","order_by":1,"name":"rifat ozpar","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"rifat","middleName":"","lastName":"ozpar","suffix":""},{"id":270956106,"identity":"404c4f8b-9815-43c5-8d5d-8f17340ba366","order_by":2,"name":"Gizem MESUT","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"Gizem","middleName":"","lastName":"MESUT","suffix":""},{"id":270956107,"identity":"89cf334f-f7d9-487e-ae73-cb39f6ba1de6","order_by":3,"name":"farid hojjati","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"farid","middleName":"","lastName":"hojjati","suffix":""},{"id":270956108,"identity":"7ff3100c-5d1d-4b9b-b082-92b56fef0707","order_by":4,"name":"serhat gokce","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"serhat","middleName":"","lastName":"gokce","suffix":""},{"id":270956109,"identity":"f4635b4e-632c-432a-8ffc-be9f39fd5354","order_by":5,"name":"deniz sigirli","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"deniz","middleName":"","lastName":"sigirli","suffix":""},{"id":270956110,"identity":"a322b24c-1bee-4ae8-8b9b-a5533564a6db","order_by":6,"name":"emel oguz-akarsu","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"emel","middleName":"","lastName":"oguz-akarsu","suffix":""},{"id":270956111,"identity":"72cc7c32-ec2c-4db4-847d-6c69982fe65e","order_by":7,"name":"furkan saridas","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"furkan","middleName":"","lastName":"saridas","suffix":""},{"id":270956112,"identity":"ebae0ea3-0045-45c5-823a-3b4bf8381e2c","order_by":8,"name":"mustafa bakar","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"mustafa","middleName":"","lastName":"bakar","suffix":""},{"id":270956113,"identity":"7d1fb54e-618c-4c70-975d-3e0759da8675","order_by":9,"name":"bahattin hakyemez","email":"","orcid":"","institution":"Uludağ University","correspondingAuthor":false,"prefix":"","firstName":"bahattin","middleName":"","lastName":"hakyemez","suffix":""}],"badges":[],"createdAt":"2024-01-15 21:59:06","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3867836/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3867836/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":50807923,"identity":"9e26cbd9-abc6-4515-8f26-49f24bbcc98e","added_by":"auto","created_at":"2024-02-07 16:33:09","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":197818,"visible":true,"origin":"","legend":"\u003cp\u003eBasilar artery segments: proximal from the vertebrobasilar junction to the origin of the AICA, mid from the AICA to the origin of the SCA, and distal after the origin of the SCA. AICA, anteroinferior cerebellar artery; ASA, anterior spinal artery; PCA, posterior cerebral artery; PCOM, posterior communicating artery; PICA, posteroinferior cerebellar artery; SCA, superior cerebellar artery; VA, vertebral artery.\u003c/p\u003e","description":"","filename":"figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-3867836/v1/698744c26690968c963f63da.png"},{"id":50808243,"identity":"a84ad668-8c46-40e7-bd7f-0b68d88e677a","added_by":"auto","created_at":"2024-02-07 16:41:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1412856,"visible":true,"origin":"","legend":"\u003cp\u003eA: Appearance of pre-occlusive stenosis in the basilar artery,2B: Multiple acute lacunes \u0026nbsp;developing due to pontine perforating artery ischemia, 2C: acute hemodynamic infarcts in the right cerebellar hemisphere and late subacute hemodynamic infarcts in the left cerebellar hemisphere, 3D: Scattered infarcts developed due to the process in both cerebellar hemispheres\u003c/p\u003e","description":"","filename":"figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-3867836/v1/1330748681ff5b1a4a37fe38.png"},{"id":50807922,"identity":"dc222d8f-f1b4-4192-a416-a5f41ad41d71","added_by":"auto","created_at":"2024-02-07 16:33:09","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":34008,"visible":true,"origin":"","legend":"\u003cp\u003eArea under the roc curves (AUC) for the relationship between the degree of stenosis and symptomatology of proximal basilar artery stenosis\u003c/p\u003e","description":"","filename":"figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-3867836/v1/2dbdc9d2d146ca43915387cd.png"},{"id":50808242,"identity":"5215e403-8258-4f33-a8bf-fcd2f2b6273d","added_by":"auto","created_at":"2024-02-07 16:41:09","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":34632,"visible":true,"origin":"","legend":"\u003cp\u003eArea under the roc curves (AUC) for the relationship between the degree of stenosis and symptomatology of mid-basilar artery stenosis\u003c/p\u003e","description":"","filename":"figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-3867836/v1/2cfbafe8edf2e2495a953493.png"},{"id":54339928,"identity":"c4345f8e-7fe5-4a0b-8a16-f5315e5e4fa7","added_by":"auto","created_at":"2024-04-09 04:44:45","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1592388,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3867836/v1/7b2cad5a-83ba-4dce-b0f6-96042916e1dd.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eCharacteristics That Affect the Long-term Clinical Outcome and Stroke Recurrence in Ischaemic Stroke Patients With Basilar Artery Atherosclerosis\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003ePosterior circulation stroke affects the vertebrobasilar artery system and constitutes 20\u0026ndash;25% of all ischaemic stroke (IS) cases [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. It differs from anterior circulation stroke in etiopathogenesis. Studies have shown that the most common stroke aetiology in posterior circulation stroke is IS due to large artery atherosclerosis [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The basilar artery (BA) is the major artery of the posterior circulation and provides the main blood supply to this vascular region [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. The incidence of BA occlusion isn\u0026rsquo;t known exactly, but it is estimated to account for 1% of all stroke cases [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Although atherosclerotic disease of the BA is rare, it is characterised by high mortality and stroke recurrence [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Atherosclerotic disease of the BA can have varied presentations and is asymptomatic in some patients. The clinical spectrum in symptomatic patients includes heterogeneous features that can range from minor deficits to coma and death [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. New endovascular treatment options, which are increasingly available, have expanded the treatment options for these patients. On the basis of the data from the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial, BA stenting is recommended for patients with recurrent IS with symptomatic BA atherosclerotic stenosis who are undergoing aggressive medical treatment [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. However, even under aggressive medical treatment, the risk of recurrent IS due to intracranial atherosclerotic stenosis remains high. IS is a heterogeneous group of diseases precipitated by many complicated mechanisms [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. This study aimed to determine the incidence rate and symptoms of atherosclerotic disease of the BA in an IS population and the factors that affect the clinical outcomes and IS recurrence in symptomatic patients.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cp\u003eIn this study, 107 IS patients with atherosclerotic stenosis in the BA who were followed up in our tertiary center between 1 January 2019 and 1 January 2022, were included in the study.\u003c/p\u003e \u003cp\u003e The Clinical Research Ethics Committee of the Bursa Uludag\u003c/p\u003e \u003cp\u003e University, Faculty of Medicine approved the study (26 September 2023;2023-18/24). Need for informed consent was waived by The Clinical Research Ethics Committee of the Bursa Uludag University, Faculty of Medicine. This study was carried out in accordance with the guidelines in the Declaration of Helsinki.\u003c/p\u003e \u003cp\u003eThe inclusion criteria for the study were patients diagnosed with IS with clear aetiology and atherosclerotic stenosis in the BA in the emergency who were regularly examined at the neurology outpatient clinic.\u003c/p\u003e \u003cp\u003eThe exclusion criteria were failure to clarify the stroke aetiology, BA occlusion, and non-atherosclerotic stenosis (dissection, moyamoya disease) in the BA, being vertebral artery or posterior cerebral artery has more than 50 percent atherosclerotic stenosis.\u003c/p\u003e \u003cp\u003eBetween 1 January 2018 and 1 January 2022, 3214 patients were followed up, and 107 patients were included in the study according to the inclusion and exclusion criteria. All patients diagnosed with IS in the emergency department were admitted to the neurology service for further examination and treatment.\u003c/p\u003e \u003cp\u003eAll patients underwent brain and neck computed tomographic (CT) angiography, cranial magnetic resonance imaging (MRI), transthoracic echocardiography, and 24-hour rhythm Holter monitoring. In the epicrisis, their medical histories were recorded, including previous diseases, smoking habits, coronary artery disease (CAD), congestive heart failure, hypertension (HT), and diabetes mellitus (DM). The patients' hemogram, biochemistry results, low-density-lipoprotein (mg/dL), (LDL) levels, and HbA1c (%) values were evaluated during their hospitalisation in the neurology ward.\u003c/p\u003e \u003cp\u003eDuring clinical follow-up, the aim was to keep the LDL level\u0026thinsp;\u0026lt;\u0026thinsp;100 mg/dL, and medical treatment was started for all the patients.\u003c/p\u003e \u003cp\u003eThe patients with HbA1c levels\u0026thinsp;\u0026gt;\u0026thinsp;7% were evaluated on the basis of endocrinology findings, and HbA1c and LDL values were checked every 3 months. The patients' brain and neck CT angiograms were evaluated by a radiologist (B.H.) with 23 years of neuroradiology experience who was blinded to the clinical findings. The degree of stenosis was determined using the NASCET method.\u003c/p\u003e \u003cp\u003eThe posterior cerebral collateral score was determined by evaluating the posterior communicating arteries (PCOMs). All patients were evaluated for the presence and diameter of both PCOMs, according to the following scores: dominant PCOM, 2 points; hypoplastic PCOM, 1 point; and no PCOMs, 0 points. The total scores ranged from 0 to 4. Scores from 0 to 1 were considered bad collateral scores, and scores from 2 to 4 were good collateral scores.\u003c/p\u003e \u003cp\u003eThe patients' stroke aetiologies were determined using the TOAST (trial of ORG 10172 in acute stroke treatment) classification [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. A BA stenosis causing an IS was considered symptomatic. Whether the BA was symptomatic or not was decided by a stroke neurologist. The BA was evaluated in 3 segments: proximal, middle, and distal (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe stroke mechanisms were evaluated by dividing them into 4 types: artery-to-artery embolism, perforatory stroke, haemodynamic stroke, and IS due to BA occlusion (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIn the 3rd month, the patients' clinical outcomes were determined using the modified Rankin scale (0\u0026ndash;2, favourable outcomes and 3\u0026ndash;6, unfavourable clinical outcomes).\u003c/p\u003e \u003cp\u003eAll the patients underwent regular checkups at the neurology outpatient clinic, where any stroke recurrence was recorded. The patients were followed in accordance with the American Heart Association guidelines. BA stenting was performed in patients with recurrent IS who were undergoing aggressive medical treatment.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe patients with atherosclerotic stenosis of the BA were categorised as either symptomatic or non-symptomatic. Receiver-operating characteristic (ROC) analysis was performed to determine the cut-off value of the degree of stenosis. The patients with symptomatic BA stenosis were then categorised according to whether they had stroke recurrence or not and their clinical outcomes.\u003c/p\u003e \u003cp\u003eThe clinical properties of the patients in both groups were analysed and compared. A statistical analysis was implemented using the IBM SPSS Statistics 25.0 package (IBM Corp., Armonk, NY). The Shapiro-Wilk test was used to determine the normality of the data distribution. Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD values were determined for the normally distributed variables, and median (Q1\u0026ndash;Q3) values were determined for the non-normally distributed variables. An independent sample T test was performed to analyze the normally distributed variables between the two independent groups, and the Whitney U test was performed for the non-normally distributed variables.\u003c/p\u003e \u003cp\u003eFrequencies and percentages were determined for the categorical variables. The Pearson chi-square test or Fisher exact test was performed to analyse the categorical variables for comparison between the groups. The binary logistic regression model included the variables found to be significant in the univariate analyses. Differences with p values\u0026thinsp;\u0026gt;\u0026thinsp;0.05 were recognised as statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003eA total of 3285 patients with acute IS were followed up between January 2018 and January 2022 at the Department of Neurology of the Uludag University Faculty of Medicine. A total of 107 patients with atherosclerotic stenosis in the BA who met the inclusion criteria were included in the study. Of these patients, 39 were female, and 68 were male. The mean age was 67.98 \u0026plusmn; 9.33 years for all the patients, 67.08 \u0026plusmn; 9.51 years for the male patients, and 69.53 \u0026plusmn; 8.90 years for the female patients, indicating statistically similar mean ages between the male and female patients (p \u0026gt; 0.05). When the patients\u0026apos; risk factors were evaluated, 88 patients had HT, 64 had diabetes mellitus (DM), 59 were smokers, 31 had congestive heart failure, 45 had CAD, and 15 had atrial fibrillation (AF).\u003c/p\u003e\n\u003cp\u003eAccording to stroke aetiology, 77 patients had an IS due to large artery atherosclerosis, 15 had an IS due to cardioembolism, 8 had an IS due to small vessel disease, 1 had an IS due to other causes, and 6 had an IS due to undetermined causes.\u003c/p\u003e\n\u003cp\u003eWhen the location of the BA stenosis was examined, atherosclerotic stenosis was detected in the proximal basilar segment in 56 patients, in the mid-basilar segment in 59, and in the distal basilar segment in 7. The BA atherosclerotic stenosis was multisegmented in 13 patients and symptomatic in 69 patients. BA stenting was performed in 29 patients.\u003c/p\u003e\n\u003cp\u003eAs shown in Table 1, the BA atherosclerotic stenosis was symptomatic in 32 of the 56 patients with atherosclerotic stenosis in the proximal segment of the BA. A ROC analysis was performed to evaluate the level of stenosis in the patients with atherosclerotic stenosis in the proximal BA and to differentiate the symptomatic and non-symptomatic patients. The area under the ROC was 0.784 (p \u0026lt; 0.001). The cut-off value was \u0026gt;70%, and the sensitivity and specificity corresponding to this cut-off value were 54.55% and 95.83%, respectively (Figure 3). Of the patients with symptomatic proximal BA atherosclerosis, 24 had an unfavourable clinical outcome, and 8 had a favourable clinical outcome. IS recurrence was observed in 15 patients with symptomatic proximal artery stenosis. When the stroke mechanisms were evaluated, artery-to-artery embolism occurred in 19 patients; penetrating artery infarction, in 18; haemodynamic stroke, in 6; and BA occlusion, in 4. The stroke in 13 patients occurred with a mixed mechanism.\u003c/p\u003e\n\u003cp\u003eThe BA atherosclerotic stenosis was symptomatic in 42 of the 59 patients with atherosclerotic stenosis in the mid-basilar segment. A ROC analysis was performed to evaluate the level of stenosis in the patients with atherosclerotic stenosis in the mid-basilar segment and to differentiate between the symptomatic and non-symptomatic patients. The area under the ROC was 0.718 (p \u0026lt; 0.001). The cut-off value was \u0026gt;70%, and the sensitivity and specificity corresponding to this cut-off value were 52.38% and 88.24%, respectively (Figure 4). Of the patients with symptomatic mid-basilar atherosclerosis, 30 had a favourable clinical outcome, and 12 had an unfavourable clinical outcome. IS recurrence was observed in 15 patients with symptomatic mid-basilary stenosis. When the stroke mechanisms were evaluated, artery-to-artery embolism occurred in 15 patients; IS due to penetrating artery infarction, in 31; IS with a mixed mechanism, in 7; and BA occlusion, in 5. IS occurred with a mixed mechanism in 15 patients.\u003c/p\u003e\n\u003cp\u003eWhen the demographic, clinical, and radiological properties of the IS patients with symptomatic BA stenosis and stroke recurrence were examined, the significant variables were artery-to-artery embolism (p = 0.027), BA occlusion (p \u0026lt; 0.001), or a mixed mechanism as the stroke mechanism (p \u0026lt; 0.001); haemoglobin level (p = 0.030); and degree of stenosis (p \u0026lt; 0.001; Table 2).\u003c/p\u003e\n\u003cp\u003eHowever, no significant statistical relationship was found between stroke recurrence in the patients with symptomatic BA stenosis and age; sex; the presence of DM, HT, smoking, AF, congestive heart failure, or CAD; clinical outcomes; haemodynamic infarction or perforatory stroke as the stroke mechanism; and stenotic segments of the BA (p \u0026gt; 0.05; Table 2).\u003c/p\u003e\n\u003cp\u003eAmong the variables with a statistically significant relationship with symptomatic BA atherosclerotic stenosis and stroke recurrence that were evaluated using binary logistic regression, the most significant was the degree of stenosis (p \u0026lt; 0.001; odds ratio [OR], 1.074; Table 3).\u003c/p\u003e\n\u003cp\u003eWhen the demographic, clinical, and radiological properties of the IS patients with symptomatic BA stenosis and clinical outcomes were examined, the significant variables were sex (p = 0.033), congestive heart failure (p = 0.050); artery-to-artery embolism (p = 0.008), BA occlusion (p \u0026lt; 0.001), or mixed mechanism as the stroke mechanism (p = 0.050); stenosis in the proximal basilary segments (p = 0.007); and stenosis in the mid-basilary segments (p = 0.020; Table 4).\u003c/p\u003e\n\u003cp\u003eHowever, no significant statistical relationships were found between the clinical outcomes of the patients with symptomatic BA stenosis and age; the presence of HT, DM, smoking, AF, or congestive heart failure; perforatory stroke, haemodynamic stroke, or BA occlusion as the stroke mechanism; stenosis in the distal basilar segment; multi-segment stenosis; stroke recurrence; degree of stenosis; and BA stenting procedure (p \u0026gt; 0.05; Table 4).\u003c/p\u003e\n\u003cp\u003eAmong the variables with a statistically significant relationship with symptomatic BA atherosclerotic stenosis and unfavourable clinical outcomes that were evaluated using binary logistic regression, the most significant were sex (p = 0.06; OR, 9.776), congestive heart failure (p = 0.013; OR, 10.133), artery-to-artery embolism as the stroke mechanism (p = 0.042; OR, 3.874), atherosclerotic stenosis in the proximal BA (p = 0.022; OR, 4.716; Table 5).\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eAccording to the results of this study, the degree of atherosclerotic stenosis in symptomatic BA was an independent risk factor of stroke recurrence. The independent risk factors of unfavourable clinical outcomes in these patients were female sex, stenosis in the proximal segment, artery-to-artery embolism as the stroke mechanism, and congestive heart failure. The incidence of intracranial atherosclerotic disease is increasing with the ageing of society. A recent study reported that intracranial atherosclerotic stenosis most frequently occurs in the BA in IS patients [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. In patients with IS due to intracranial atherosclerotic disease, stenting is recommended in the presence of recurrent IS under aggressive medical treatment. This recommendation is based on data from the SAMMPRIS trial [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. However, even under aggressive medical treatment, the risk of recurrent IS due to intracranial atherosclerotic stenosis remains high.\u003c/p\u003e \u003cp\u003eIn our study, atherosclerotic stenosis of the BA was detected in 107 patients, of whom 69 (64.48%) were symptomatic. The mean follow-up period of the asymptomatic patients was 28.00\u0026thinsp;\u0026plusmn;\u0026thinsp;18.034 months. None of the patients in the asymptomatic group had IS under aggressive medical treatment. The mean follow-up period in the symptomatic group was 25.53\u0026thinsp;\u0026plusmn;\u0026thinsp;17.842 months. Of the 69 symptomatic patients, 30 (43.47%) had recurrent IS during the follow-up period. As this incidence rate was based on real-life data, it is much higher than those reported in randomised studies [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn our study, stenosis was detected in the proximal BA in 32 patients, in the mid-basilar segment in 42, and in the distal BA in 6. The stenosis was multisegmented in 13 patients. According to the findings of this study, atherosclerotic stenosis was most frequent in the mid-basilar segment but was rare in the distal BA. Similar incidence rates were obtained from the data reported by Edgar et al. [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe degree of stenosis was established to be an independent risk factor of stroke recurrence in patients with symptomatic BA stenosis. According to the data from the Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis (WASID) trial, the degree of stenosis is related to stroke recurrence [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. In our study, the independent risk factor of unfavourable clinical outcomes was female sex. The relationships between sex and IS and atherosclerosis are complex. Atherosclerosis has a different course in women and men. Atherosclerotic lesions progress slowly starting from the fourth and fifth decades in men and progress rapidly in women, starting from the sixth decade [\u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Studies have indicated that stroke has a worse clinical outcome in women [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. To our knowledge, no studies have reported the relationship between sex and IS due to BA atherosclerosis. Data from randomised studies that evaluated symptomatic intracranial atherosclerotic stenosis have indicated that while no sex-related difference was found in the Chinese Intracranial Atherosclerosis (CICAS) trial, female sex was found to be a poor prognostic factor in the WASID trial [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe most common stroke mechanism in patients with symptomatic BA atherosclerosis is perforatory stroke. MRI studies have shown that BA plaques have a long distribution and affect the ventral, dorsal, and lateral walls equally. These plaques do not have the same characteristics as those in the coronary and middle cerebral arteries. In addition, plaques in the BA tend to settle adjacent to the orifices of the penetrating arteries [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. This can explain why the most common stroke mechanism is perforatory stroke.\u003c/p\u003e \u003cp\u003eArterial-to-artery stroke mechanism is an independent risk factor of unfavourable clinical outcomes. A recent study found a correlation between the morphological features of plaques and IS mechanism due to symptomatic posterior intracranial atherosclerosis. The authors found that unstable plaques with a higher plaque burden and irregular surfaces were symptomatic of artery-to-artery embolism [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. In intracranial atherosclerotic disease, IS due to an artery-to-artery embolic stroke mechanism is a poor prognostic factor [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eUnfavourable clinical outcome is another independent risk factor. Congestive heart failure is quite common in the stroke population. It is also an important risk factor of IS in the normal population [\u003cspan additionalcitationids=\"CR24 CR25\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Morbidity and mortality rates were found to be higher in IS patients with congestive heart failure [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. This relationship may be the result of the close relationship between heart failure and atherosclerotic vascular disease.\u003c/p\u003e\n\u003ch3\u003eLimitations of the study\u003c/h3\u003e\n\u003cp\u003eThe major limitation of this study is due to its retrospective nature and data from a single centre. More accurate information can be obtained through multi-centre prospective studies.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe most remarkable result of our study is that clinical outcomes were closely related to the female sex, artery-to-artery embolism as the stroke mechanism, and stenosis in the proximal segment. In patients with symptomatic BA stenosis, studies are needed to examine the effects of IS mechanisms and plaque morphologies on long-term stroke recurrence and clinical outcomes. Stroke mechanisms must be evaluated more clearly so that individualised treatments can be provided to these patients.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eAuthor Contribution:Concepts: YDDesign: YDDefinition Of İntellectual Content:MB, YDLiterature Search:YD, GM, FH, EOA, FSClinical Studies: YD, GM, FH, EOA, FSExperimental Studies:-Data Acquisition:YD, GM, FH, EOA, FSData Analysis: DS, YD, RO, GM, FH, SGStatistical Analysis: DS, YDManuscript Preparation:YD, EOA, FSManuscript Editing: MB, BHManuscript Review: MB, BHGuarantor: YDCorresponding Author: YD\u003c/p\u003e\u003ch2\u003eData availability:\u003c/h2\u003e \u003cp\u003eAll authors accept to share data if it is necessary\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMerwick A., Werring D. Posterior circulation ischaemic stroke. Bmj. 2014; 348:3175.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePirson F., et al. Etiology of large vessel occlusion posterior circulation stroke: results of the MR CLEAN Registry. Stroke 2022;53:2468\u0026ndash;2477.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCaplan LR.,et al. New England medical center posterior circulation registry. Ann Neurol 2004;56:389\u0026ndash;98.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCaplan LR. Primer on cerebrovascular diseases. London, United Kingdom: Academic Press is an imprint of Elsevier; 2017.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIsraeli-Korn SD., et al. Ischemic stroke due to acute basilar artery occlusion: proportion and outcomes. Isr Med Assoc J 2010; 12: 671\u0026ndash;75.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSamaniego EA., et al. Stroke mechanisms and outcomes of isolated symptomatic basilar artery stenosis.Stroke Vasc Neurol. 2019; 4:189\u0026ndash;197.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMattle HP., Arnold M., Lindsberg PJ., Schonewille WJ., Schroth G. Basilar artery occlusion. Lancet Neurol 2011; 10: 100214.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVoetsch B., DeWitt LD., Pessin MS., Caplan LR. Basilar Artery Occlusive Disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2004;61(4):496\u0026ndash;504. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/archneur.61.4.496\u003c/span\u003e\u003cspan address=\"10.1001/archneur.61.4.496\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleindorfer, D.O., et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021, 52, 364\u0026ndash;467\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDerdeyn, C. P et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. The Lancet, 2014;383(9914), 333\u0026ndash;341.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDin\u0026ccedil; Y., Bakar M., Hakyemez B. Causes of ischemic stroke in patients with atrial fibrillation. Turk J Neurol 2020; 26: 311\u0026ndash;315.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdams Jr., et al. \"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.\" stroke 24.1 (1993): 35\u0026ndash;41.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFeng X., Chan KL., Lan L., Abrigo J., Liu J., Fang H., Xu Y., Soo Y., Leng X., Leung TW. Stroke mechanisms in symptomatic intracranial atherosclerotic disease: classification and clinical implications. Stroke. 2019;50:2692\u0026ndash;2699.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDin\u0026ccedil; Y., et all.Evaluation of intracranial atherosclerotic disease risk factors in patients with acute ischeamic stroke. Neurology Asia 2023,28(4):809\u0026ndash;816.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChimowitz MI., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305\u0026ndash;1316.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBae HJ., et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis 2007;24:355\u0026ndash;60.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eL\u0026oacute;pez-Cancio E., et al. The Barcelona-Asymptomatic Intracranial Atherosclerosis (AsIA) study: prevalence and risk factors. Atherosclerosis. 2012;221:221\u0026ndash;225.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePu Y., et al. Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke 2013;44:2109\u0026ndash;14.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReeves MJ., et all. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915\u0026ndash;926.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePu Y., et all. Chinese IntraCranial AtheroSclerosis (CICAS) Study Group: Sex differences do not exist in outcomes among stroke patients with intracranial atherosclerosis in China: subgroup analysis from the Chinese intracranial atherosclerosis study. Neuroepidemiology 2017;48:48\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu J., et al. Plaque distribution of low-grade basilar artery atherosclerosis and its clinical relevance. BMC Neurol 2017;17(1), 1\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong X,. et al. Association of Plaque Morphology With Stroke Mechanism in Patients With Symptomatic Posterior Circulation ICAD. Neurology, 2022,99: 2708\u0026ndash;2717.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke. 2018;20(1):33\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGottdiener JS., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJelinek MV., Ansari MZ. Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. Aust N Z J Med. 1998;28:799\u0026ndash;804.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e22. Witt, BJ. et al. Ischemic stroke after heart failure: a community-based study. Am Heart J. 2006;152:102\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSiedler, G. et all. Heart failure in ischemic stroke: relevance for acute care and outcome. Stroke, 2019;50(11): 3051\u0026ndash;3056.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1: Clinical properties of \u0026nbsp;proxymal and mid-basilar artery stenosis\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eProperties\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;Symptomatic proximal basilar artery stenosis\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en=56\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSymptomatic mid-basilar stenosis\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en=59\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSymptomatic basilar artery stenosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e32(57.14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e42(71.18%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke recurrence due to basilary artery stenosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e15(26.78%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.42%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke mechanism\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003eartery-to-artery embolism due to basilary artery stenosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e19(33.92%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.42%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003ePerforators stroke due to basilary artery stenosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e18(32.14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e31(52.54%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003eHemodynamic stoke due to basilary artery stenosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e6(10.71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e7(11.86%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003eStroke due to basilar artery occlusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e4(7.14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e5(8.47%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003eMix mechanism\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e13(23.21%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.42%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eFavorable clinical outcome\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e8(14.28%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e30(50.84%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eUnfavorable clinical outcome\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e24(42.85%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e12(20.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"49.917355371900825%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eFollow-up perıod of patıents\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(Month)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.611570247933884%\" valign=\"top\"\u003e\n \u003cp\u003e23.50 \u0026plusmn;17.63\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.47107438016529%\" valign=\"top\"\u003e\n \u003cp\u003e29.93 \u0026plusmn;17.78\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eTable 2. Evaluation of variables affecting stroke recurrence in acute ischemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eIschemic Stroke Due to Symptomatic Basilar Artery Atherosclerotic stenosis with Stroke Recurrence\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.801324503311257%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eIschemic Stroke Due to Symptomatic Basilar Artery Atherosclerotic stenosis without Stroke Recurrence\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=39)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.76158940397351%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eAge*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e66.50\u0026plusmn;7.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e67.64\u0026plusmn;10.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.614\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eSex**\u003c/p\u003e\n \u003cp\u003e(male gender)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e19(63.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e19(48.71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.226\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e19(63.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e26(66.66%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.773\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e26(86.66%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e31(79.48%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.435\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eSmoker**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e16(53.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e20(51.28%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.886\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eAtrial fibrilation**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e16(53.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e20(51.28%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eCongestive heart failure**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e4(13.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e10(25.64%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.208\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eCoroner artery disease**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e10(33.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e15(38.46%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.660\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eHemoglobin(g/dL)*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e13.25(11.85,14.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e13.80(12.58,14.70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.030\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eLDL(mg/dL)*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e151.50(100.00,185.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e138.50(112.25,174.75)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.607\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"5\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke mechanism\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eArtery-to-artery\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eembolism **\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e18(60%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e10(25.64%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.027\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003ePerforators infarction**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e16(48.48%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e28(71.79%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.114\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eHemodynamic infarction\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e7(23.23%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e5(12.82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.253\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eBasilar artery occlusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e9(30%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0(0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eMix mechanism\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e18(60%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e8(20.51%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"5\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStenotic segment of the basilar artery\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eProximal segment**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e15(50%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e17(43.58%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.506\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eMiddle segment**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e15(50%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e27(69.23%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.105\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eDistal segment**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e3(10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e3(7.69%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eMultisegment stenosis**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e3(10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e6(15.28%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.722\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStenosis degree(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e66,28\u0026plusmn;20.70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e85.50\u0026plusmn;10.77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003eClinical outcome**\u003c/p\u003e\n \u003cp\u003eUnfavorable clinical outcome\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e11(%36.66)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e11(%28.20)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.455\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ePosterior collateral scores\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(poor collateral scores)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e13(43.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e14(35.89)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.271523178807946%\" valign=\"top\"\u003e\n \u003cp\u003e0.530\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSignificant variables are shown in bold. *Mann-Witney U test, **Pearson chi-square test/continuity correction test/Fisher Exact test.Abbreviations: LDL, Low-Density Lipoprotein.\u003c/p\u003e\n\u003cp\u003eTable 3. Significant variables of stroke recurrence in acute ischaemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"604\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"43.70860927152318%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ep-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eOdds ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.072847682119205%\" valign=\"top\"\u003e\n \u003cp\u003elower\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.05298013245033%\" valign=\"top\"\u003e\n \u003cp\u003eupper\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e%95 C.I\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"43.70860927152318%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke mechanism being artery to artery embolism\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eRef: Absent vs present\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e0.151\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e2.315\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.072847682119205%\" valign=\"top\"\u003e\n \u003cp\u003e0.736\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.05298013245033%\" valign=\"top\"\u003e\n \u003cp\u003e7.283\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"43.70860927152318%\" valign=\"top\"\u003e\n \u003cp\u003eStenosis degree\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e1.074\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.072847682119205%\" valign=\"top\"\u003e\n \u003cp\u003e1.029\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.05298013245033%\" valign=\"top\"\u003e\n \u003cp\u003e1.119\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"43.70860927152318%\" valign=\"top\"\u003e\n \u003cp\u003eHeamoglobin(g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e0.393\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.582781456953642%\" valign=\"top\"\u003e\n \u003cp\u003e0.986\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.072847682119205%\" valign=\"top\"\u003e\n \u003cp\u003e0.899\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.05298013245033%\" valign=\"top\"\u003e\n \u003cp\u003e1.043\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSignificance of the model p\u0026lt;.001. Significant variables are shown in bold. Ref = references, vs = versus.\u003c/p\u003e\n\u003cp\u003eTable 4: Table 2. Evaluation of variables affecting clinical outcomes in acute ischemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ePatients with acute stroke due to basilar artery stenosis with unfavorable clinical outcome\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en=22\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.655629139072847%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ePatients with acute stroke due to basilar artery stenosis with favorable clinical outcome\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en=47\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.907284768211921%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e70.00\u0026plusmn;7.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e65.80\u0026plusmn;9.55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.078\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eSex\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(male gender)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e8(%36.36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e30(%52.63)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.033\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e18(%81.81)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e39(%68.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eDiyabetes mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e16(%72.72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e29(%61.70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.370\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eSmoker\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e9(%40.90)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e27(%57.44)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.200\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eAtrial fibrilation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e1(%4.54)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e4(%8.51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eCongestive heart failure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e8(%36.36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e6(%17.76)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.050\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eCoroner artery disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e9(%40.90)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e16(%34.04)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.580\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke mechanism\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eArtery-to-artery embolism\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e15(%68.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e16(%34.04)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.008\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003ePerforators stroke\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e11(%50.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e33(%70.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.104\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eHemodynamic stroke\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e4(%18.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e8(%17.02)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eBasilar artery occlusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e5(%22.72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e4(%8.51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.132\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eMix mechanism\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e12(%54.54)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e14(%29.78)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.050\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"87.58278145695364%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSegment of basilary artery\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eProximal segment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e15(%68.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e17(%36.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eMid-basilar segment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e9(%40.90)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e33(%70.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.020\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eDistal segment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e3(%13.63)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e3(%6.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.375\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003eMulti-segment stenosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e4(%18.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e5(%10.63)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.452\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke recurrence\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e11(%50.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e19(%40.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.455\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eDegree of stenosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e74.00(57.50,95,00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e80.00(60.00,90.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.891\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBasilar artery stenting\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e6(%27.27)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e21(%44.68)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.167\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.14569536423841%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ePosterior collateral scores\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(poor collateral scores)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.29139072847682%\" valign=\"top\"\u003e\n \u003cp\u003e8(%36.66)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.14569536423841%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e19(%40.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.417218543046358%\" valign=\"top\"\u003e\n \u003cp\u003e0.747\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSignificant variables are shown in bold. *Mann-Witney U test, **Pearson chi-square test/continuity correction test/Fisher Exact test.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Significant variables of clinical outcome in acute ischaemic stroke patients with atherosclerotic stenosis in the symptomatic basilar artery\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.429752066115704%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.735537190082646%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ep-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eOdds ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.049586776859504%\" valign=\"top\"\u003e\n \u003cp\u003elower\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003eUpper\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e%95 C.I\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.429752066115704%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSex\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eRef: female gender\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.735537190082646%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.006\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e9.776\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.049586776859504%\" valign=\"top\"\u003e\n \u003cp\u003e1.049 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e14.285\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.429752066115704%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCongestive heart failure\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eRef: present vs absent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.735537190082646%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.013\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e10.133\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.049586776859504%\" valign=\"top\"\u003e\n \u003cp\u003e1.625 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e63.181\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.429752066115704%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eStroke mechanism being artery-to-artery embolism\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eRef: present vs absent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.735537190082646%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.042\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e3.874\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.049586776859504%\" valign=\"top\"\u003e\n \u003cp\u003e1.049\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e14.285\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.429752066115704%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eAtherosclerotic stenosis in the proximal basilar artery\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eRef: present vs absent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.735537190082646%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.022\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e4.716\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.049586776859504%\" valign=\"top\"\u003e\n \u003cp\u003e1.245 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.892561983471074%\" valign=\"top\"\u003e\n \u003cp\u003e17.868\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSignificance of the model \u0026lt; 0.001. Significant variables are shown in bold. Ref = references, vs = versus.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"intracranial atherosclerotic disease, basilar artery infarction, basilar artery stenting, acute ischaemic stroke","lastPublishedDoi":"10.21203/rs.3.rs-3867836/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3867836/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e \u003cb\u003eİntroduction\u003c/b\u003e: Posterior circulation stroke differs from anterior circulation stroke in etiopathogenesis. Studies have shown that the most common stroke aetiology in posterior circulation stroke is ischemic stroke due to large vessel atherosclerosis. However, even under aggressive medical treatment, the risk of recurrent ischemic stroke in ischemic stroke due to intracranial atherosclerotic stenosis remains high. This study aims to obtain the rate of atherosclerotic disease of the BA in our ischemic stroke population, to determine its symptomatology, and to determine the factors affecting clinical outcome and ischaemic stroke recurrence in the symptomatic group.\u003c/p\u003e \u003cp\u003e \u003cb\u003eMaterial method\u003c/b\u003e: we included 107 patients who were diagnosed with acute ischemic stroke with basilar artery stenosis.\u003c/p\u003e \u003cp\u003eResults\u003c/p\u003e \u003cp\u003eAccording to the results of our study, the degree of stenosis in atherosclerotic stenosis of the symptomatic BA was found to be an independent risk factor for stroke recurrence. Independent risk factors for unfavourable clinical outcomes in these patients were determined as female gender, stenosis being in the proximal segment, stroke mechanism being from artery to artery embolism, and congestive heart failure.\u003c/p\u003e \u003cp\u003eDiscussion\u003c/p\u003e \u003cp\u003eThe most striking result of our study is that clinical outcome was found to be closely related to the female gender, the stroke mechanism being artery-to-artery embolism, and the stenosis is in the proximal segment. If stroke mechanisms were evaluated more clearly, it would likely help provide individualized treatments.\u003c/p\u003e","manuscriptTitle":"Characteristics That Affect the Long-term Clinical Outcome and Stroke Recurrence in Ischaemic Stroke Patients With Basilar Artery Atherosclerosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-07 16:33:04","doi":"10.21203/rs.3.rs-3867836/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"a76c06b5-b2d3-4196-9d12-98bd950009dc","owner":[],"postedDate":"February 7th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":28600373,"name":"Health sciences/Neurology/Neurological disorders/Stroke"},{"id":28600374,"name":"Health sciences/Risk factors"},{"id":28600375,"name":"Health sciences/Neurology/Neurological disorders/Cerebrovascular disorders/Stroke"}],"tags":[],"updatedAt":"2024-04-09T04:44:22+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-07 16:33:04","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3867836","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3867836","identity":"rs-3867836","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}